Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to be more efficient than its blockbuster drugs currently on the market, Ozempic and Wegovy.
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk shares pop 9% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms
Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial
Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes treatment Ozempic said its phase 1b/2a trial covered 125 overweight people.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Surprising New Research Links Common Medications to Reduced Dementia Risk
New research suggests that commonly used medications like antibiotics, antivirals, and anti-inflammatories could lower the ...
Medicare announces 15 new drugs chosen for price negotiations, including popular weight loss drug Ozempic
Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...
IFLScience on MSN3d
New Breast Cancer Drug Kills Mouse Tumors In Single Dose
More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.
freightwaves.com1d
Running on Ice: New drug formulas could mean less cold chain involvement
A new formulation for medicine that does not need cold chain support, new air cargo friendly ultra-cold storage, and the FDA ...
EurekAlert!2d
New drug shows promise in restoring vision for people with nerve damage
Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help restore vision in individuals with multiple sclerosis (MS) and other ...
New approach uses peptides to enhance anti-tumor drug formulations
A team of scientists has developed a groundbreaking approach using specially designed peptides to improve drug formulations.
'Miracle' drug innovation could see a new Wegovy launch every couple of years, Larry Summers says
Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...